|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate whether uPA/PAI-1 protein in hormone receptor-positive (HR+) breast tumor can predict prognosis in early breast cancer (BC).
|
31132475 |
2019 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
|
19082473 |
2009 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
|
17616807 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the implementation of mRNA quantification of uPA and PAI-1 in breast tumors is unable to serve as a one-to-one substitution for antigen determination by ELISA.
|
18204793 |
2008 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer.
|
18465330 |
2008 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
|
17258797 |
2007 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
|
17309181 |
2007 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to analyze uPA and PAI-1 messenger RNA (mRNA) expression by means of quantitative nucleic acid sequence-based amplification (NASBA) on 77 primary breast tumor samples and to correlate this expression with the uPA and PAI-1 protein content.
|
17709314 |
2007 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.
|
17119035 |
2006 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
|
17062678 |
2006 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
|
16945123 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
|
15646834 |
2005 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
|
14983219 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
|
14983227 |
2004 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients.
|
12556967 |
2003 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A suppression subtraction cDNA library representing mRNAs expressed at a higher level in a benign breast tumour-derived cell line relative to the malignant MCF-7A cell line contained cDNAs corresponding to mRNAs for plasminogen activator inhibitor I, annexin VIII and the EF-hand protein S100A2.
|
11076656 |
2000 |